Clinical Trial

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-09-14; most recent amendment 2025-12-15.
Status change: Completed → Active, Not Recruiting 2025-10-31
Status change: Active, Not Recruiting → Completed 2025-10-27
Status change: Recruiting → Active, Not Recruiting 2020-08-12
Status change: Not Yet Recruiting → Recruiting 2019-01-02
Trial Details
NCT Number NCT03674411
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma +3 more
Enrollment 22 participants
Start Date 2019-01-02
Primary Completion 2020-06-23 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-06